Clinical trials: Transplant Failure
End Stage Liver Failure
N-acetylcysteine in Liver Transplantation
N-acetylcysteine (NAC) is used to treat Tylenol toxicity. NAC is a rich source of the sulfhydryl group (SH) which is important for replenishing the body's glutathione stores.
- Trial name
- NAC (NCT00736541)
- Testing
- N-acetylcysteine
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Ibtesam Hilmi
Aneurysm, Graft Failure
Silver Graft All Comers Registry
This web based e-Registry will be international, multi-center and prospective. Silver Graft e-Registry to assess the long term clinical benefit of Silver Graft in an unselected patient population
- Conditions
- Aneurysm, Graft Failure, Graft Infection
- Trial name
- NCT01970605
- Testing
- Surgical reconstruction
- Where
- Germany
- Volunteers
- 230 people
- Sponsor
- B. Braun Melsungen AG
Diabetes Mellitus, Kidney Failure
Prospective Controlled Study of Posttransplant Diabetes
Research participants will be asked to undergo complete medical history, physical examination and blood tests. The purpose of these tests is to determine whether persons are predisposed to develop diabetes mellitus after kidney…
- Trial name
- NCT00006331
- Testing
- renal transplant
- Where
- United States
- Sponsor
- National Center for Research Resources (NCRR)
Pediatric ALL, Congenital Heart Disease
Virtual Remote Physiological Monitoring Program of Children With Heart Disease
Infants and children with heart conditions require treatment in children's hospitals that are typically located in large cities.
- Conditions
- Pediatric ALL, Congenital Heart Disease, Single-ventricle, Biventricular Congestive Heart Failure
- Trial name
- NCT05034354
- Testing
- Remote physiological monitoring
- Where
- Canada
- Volunteers
- 23 people
- Sponsor
- University of Alberta
Severe Aplastic Anemia
Safety and Efficacy of Patient's Own AD-MSC and AD-HSC Transplantation in Patients With Severe Aplastic Anemia
RATIONALE: It has been shown that about 30% of patients do not respond to immunosuppressive therapy or experience recurrence, and graft rejection and graft-versus-host-disease (GVHD) decrease event-free survival to 30% to 50% in…
- Trial name
- NCT02407470
- Testing
- Rabbit antithymoglobulin (ATG), Adipose derived mesenchymal stem cells ( AD-MSCs), AD-MSC transdifferentiated HSCs (AD-HSCs)
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Navy General Hospital, Beijing
Kidney Disease, End-Stage, Frailty
Virtual Home-based Physical Pre-habilitation in Kidney Transplant Candidates
The goal of this RCT is to address the feasibility of conducting a 12-week virtual pre-habilitation intervention, which includes exercise and education, in kidney transplant candidates.
- Conditions
- Kidney Disease, End-Stage, Frailty, Transplant;Failure,Kidney
- Trial name
- NCT06089473
- Testing
- Intervention Group: Exercise and education., Usual Care Only
- Where
- 2 sites in Canada
- Volunteers
- 30 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Acute Leukemias, Aplastic Anemia
Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells
Feasibility and toxicity of haploidentical transplantation of CD3/CD19 depleted stem cells in combination with a toxicity reduced conditioning regimen or with standard conditioning regimens according to underlying disease.
- Conditions
- Acute Leukemias, Aplastic Anemia, Childhood Solid Tumor
- Trial name
- NCT01919866
- Testing
- Transplantation of CD3/CD19 depleted stem cells
- Where
- 5 sites in Austria, Germany
- Volunteers
- 120 people
- Sponsor
- University Children's Hospital Tuebingen
Graft Failure
Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant
Major Objectives A. To determine whether stable allogeneic hematopoietic engraftment can be safely established in patients who have rejected (<5% T Cell Chimerism) a previous allogeneic hematopoietic stem cell graft by using an…
- Trial name
- NCT00472329
- Testing
- Allogeneic hematopoietic stem cell graft using an allogeneic SCT HLA-Identical or non-identical family donor or unrelated donors, fludarabine, TBI
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Colorado Blood Cancer Institute
Chronic Kidney Failure
Intravascular Volume Assessment Using Ultrasonography in Pediatrics Renal Transplant: A Prospective Cohort Study
This study is designed for volume assessment in pediatrics during major surgery using non-invasive tools as ultrasonography without the need of invasive techniques avoiding its complications and as a guide for fluid therapy…
- Trial name
- NCT04008953
- Testing
- ultrasonography
- Volunteers
- 16 people
- Sponsor
- Fatma Alzahraa Mohamed Ibrahim Hassan Haggag
Kidney Transplantation, End Stage Renal Disease
Live Kidney Donor Study
Kidney transplants from living donors now account for 40% of all the kidney transplants done in the United States. However, the current information on how donating a kidney can affect the donor's long term health needs further…
- Trial name
- NCT00608283
- Where
- 3 sites in United States
- Volunteers
- 8,951 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
End Stage Renal Disease (ESRD)
EndoForce Post Approval Study
The goal of this observational study is to collect long-term safety and performance data for the use of the EndoForce System for connecting a hemodialysis graft to a vein in patients with End Stage Renal Disease.
- Trial name
- NCT07146854
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Phraxis, Inc.
Graft Versus Host Disease
Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation
The purpose of this study was to test whether a new drug named visilizumab would decrease the severity of graft-versus-host disease in patients treated with a mismatched donor.
- Trial name
- NCT00720629
- Testing
- Visilizumab, Tacrolimus, Methotrexate
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Acute Graft Versus Host Disease Grade II-IV, Acute Graft vs Host Disease
Study of Gecacitinib in the Treatment of Acute Graft-Versus-Host Disease After Failure of Ruxolitinib-containing Second-line Therapy
An open-label, single-arm clinical trial to evaluate the safety and efficacy of gecacitinib tablets in patients with acute graft-versus-host disease (GVHD) who have failed or are intolerant to ruxolitinib-containing second-line…
- Trial name
- GRIT (NCT07197112)
- Testing
- Gecacitinib
- Volunteers
- 15 people
- Sponsor
- Ruijin Hospital
Heart Failure, Respiratory Failure
Donor Simvastatin Treatment in Organ Transplantation
The aim of the study is to investigate the effects of donor simvastatin treatment on ischemia-reperfusion injury after heart transplantation.
- Conditions
- Heart Failure, Respiratory Failure, Liver Failure, Kidney Failure
- Trial name
- SIMVA (NCT01160978)
- Testing
- Simvastatin 80mg, Control Rx
- Where
- Finland
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00544115
- Testing
- busulfan, cyclophosphamide, cyclosporine
- Volunteers
- 260 people
- Sponsor
- City of Hope Medical Center
Growth Failure, Chronic Liver Disease
Increlex Treatment of Children With Chronic Liver Disease and Short Stature
A major consequence of chronic liver disease in childhood is growth failure. This is because a chemical essential for growth called growth factor is created in the liver.
- Trial name
- NCT01314508
- Testing
- Increlex
- Sponsor
- University of California, Los Angeles
Heart Failure
Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients
This phase II, multi-center, open-label study will evaluate the safety and efficacy of utilizing HCV-positive donors for heart transplant in HCV-negative recipients treated with sofosbuvir 400 mg / velpatasvir 100 mg (Epclusa®).
- Trial name
- TROJAN-C (NCT03383419)
- Testing
- Epclusa
- Where
- 3 sites in United States
- Volunteers
- 15 people
- Sponsor
- Baylor Research Institute
Latent Tuberculosis, End Stage Renal Disease
One-month Latent Tuberculosis Treatment for Renal Transplant Candidates
This is a prospective, single-center, single-arm, open-label study investigating the safety, compliance and pharmacokinetics of 1-month treatment of Isoniazid, Rifapentine and Vitamin B6 in renal transplant candidates.
- Conditions
- Latent Tuberculosis, End Stage Renal Disease, Renal Transplant Candidate for Right Kidney, Renal Transplant Candidate for Left Kidney
- Trial name
- NCT05411744
- Testing
- 1 month Rifapentine, Isoniazid and Vitamin B6
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Rutgers, The State University of New Jersey
Repetition Failure
Clinical Application of Autologous Mitochondria Transplantation for Improving Oocyte Quality.
Embryo quality was ranked as one of the most important predictors in determining the success of implantation, while clinically some patients may experience repeated IVF failure due to persistent poor embryo quality.Mitochondria…
- Trial name
- NCT03639506
- Testing
- autologous mitochondria transplantation, autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI), intracytoplasmic sperm injection (ICSI)
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Heart Transplant Failure
Pilot Study: Interest of Belatacept as a Non-nephrotoxic Immunosuppressive Treatment in Cardiac Transplant Patients at Risk of Chronic Renal Failure (BELACOEUR)
Heart transplantation (TC) is the standard treatment for terminal heart failure. Chronic kidney disease (CKD) is a common complication responsible for increased mortality and morbidity.
- Trial name
- BELACOEUR (NCT04180085)
- Testing
- Belatacept Injection
- Where
- 4 sites in France
- Volunteers
- 25 people
- Sponsor
- Nantes University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.